End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
211,500 KRW | -4.30% | +1.20% | +41.57% |
03-27 | Hugel, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares. | CI |
03-27 | Hugel, Inc. authorizes a Buyback Plan. | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 56% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's enterprise value to sales, at 6020.52 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+41.57% | 1.67B | - | ||
-3.93% | 86.16B | A- | ||
+2.76% | 40.17B | A- | ||
-16.48% | 31.47B | B- | ||
+55.58% | 25.24B | A | ||
-13.58% | 15.82B | C | ||
-9.12% | 11.96B | D+ | ||
-42.56% | 11.61B | B | ||
+5.54% | 8.84B | B+ | ||
-2.11% | 7.93B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A145020 Stock
- Ratings Hugel, Inc.